BioCatalyst

Efgartigimod PH20 SC — catalyst calendar

3 verified catalyst event(s) referencing Efgartigimod PH20 SC, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-08 (month)
in 1mo
ESTIMATED
 READOUT
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With
Phase 4 · New Onset Generalized Myasthenia Gravis (gMG)
 ARGX ARGENX SE Efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-09-30
in 3mo
ESTIMATED
 READOUT
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of
Phase 2/3 · Generalized Myasthenia Gravis
 ARGX ARGENX SE Efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
2026-10-01
in 3mo
ESTIMATED
 READOUT
A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta
Phase 3 · Primary Immune Thrombocytopenia
 ARGX ARGENX SE efgartigimod PH20 SC ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.